Prosecution Insights
Last updated: April 19, 2026
Application No. 17/802,815

Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use

Non-Final OA
Filed
Aug 26, 2022
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aic246 AG & Co. Kg
OA Round
2 (Non-Final)
74%
Grant Probability
Favorable
2-3
OA Rounds
2y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
818 granted / 1102 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
58 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
47.6%
+7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1102 resolved cases

Office Action

Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 1-16 and 18-29 are pending in the instant application. Claims 24-29 are new claims and drawn to methods of use employing the elected compound of claim 13. Thus, claims 1-12 and 18-29 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 13-16 is contained herein. Information Disclosure Statement The examiner has considered the information disclosure statement filed most recently of record. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 8/7/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 11/4/2025. New Objections Claim Objections Claim 15 is objected to because the subject matter described in claim 1 (preparation method) should be incorporated into claim 15 to have the claim complete in itself tailored to represent the process of preparing the elected crystalline form of formula I. Note that the preparation method of claim 1 is drawn to all forms of the formula I and not just the crystalline form. Thus the claim is objected to. Conclusion Claims 13, 14, and 16 are allowable. Claim 15 is objected to. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Aug 26, 2022
Application Filed
Aug 05, 2025
Non-Final Rejection
Nov 04, 2025
Response Filed
Jan 13, 2026
Examiner Interview (Telephonic)
Jan 22, 2026
Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599615
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12604600
Organic Electroluminescent Element And Novel Iridium Complex
2y 5m to grant Granted Apr 14, 2026
Patent 12559494
NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
2y 5m to grant Granted Feb 24, 2026
Patent 12552807
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12545665
CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.3%)
2y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 1102 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month